云顶新耀午后涨超8% 耐赋康扩产已获国家药监局批准 公司近期战略增持I-Mab股权

智通财经
Aug 04, 2025

云顶新耀(01952)午后涨超8%,截至发稿,涨8.05%,报67.1港元,成交额4.08亿港元。消息面上,据澎湃报道,近期,有患者在社交平台上发帖称,其使用的布地奈德肠溶胶囊(商品名:耐赋康)出现缺货情况。对于缺货情况,云顶新耀表示,公司已于今年2月向国家药监局提交扩大产能的补充申请。8月4日,云顶新耀宣布,其中国首个且唯一获得完全批准的IgA肾病对因治疗药物耐赋康扩产补充申请已正式获得中国...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10